Rx for Biotech

Our guest in this podcast episode is lymphoma survivor and CAR-T cell therapy patient advocate, Brad Watts. In this episode, Brad shares his personal story battling lymphoma at the young age of 29 along with his experience receiving an innovative cell therapy. This field is transforming lives and Brad is living proof of this potential.

AI is transforming job search, recruiting and hiring practices. Our guest in this podcast episode is Steve Swan, Practice Leader at The Swan Group. Steve is an Executive Recruiter specializing in technology for the Pharmaceutical and Biotech Industry. In this episode Steve shares his insights on how AI is transforming the hiring process.

Gene therapy offers significant hope for treating sickle cell disease (SCD), a genetic disorder caused by a single mutation in the hemoglobin gene. Recent advancements have led to promising developments and FDA approvals, but challenges remain. In this podcast episode, gene therapy survivor, Jimi Olaghere, shares his journey and offers hope to others with his inspirational message and through his advocacy for patients in the sickle cell community.

In this podcast episode, hear from Diakonos Oncology President and Chief Operating Officer Jay Hartenbach, who provides an update on the company's innovative dendritic cell vaccine therapy designed to tackle some of the most challenging cancers, including glioblastoma and pancreatic cancer

Dr. Thomas Chen is a world-renowned neurosurgeon, Director of Surgical Neuro-Oncology at the University of Southern California, and the founder and CEO of NeOnc Technologies. In this podcast episode we discuss the company's unique approach to treating glioblastoma and other aggressive brain cancers.

Our guest in this podcast episode is Sreekanth Gopi, a leader in generative AI and machine learning. Sreekanth has applied AI to fields as diverse as physiological monitoring, meditation, and even generating multi-track Indian classical music. He's published award-winning research on EEG spectral analysis and adaptive quiz generation using large language models, participated in over 12 AI hackathons—winning two—and is now a Prompt Engineer at Morgan Stanley, where he fine-tunes cutting-edge LLM interactions for real-world applications. In this episode we explore how AI is redefining stress management and revolutionizing real-time physiological data applications. Tune in to learn about the world of generative artificial intelligence— and looking at its transformative potential in mental health and stress management.

Arvinas is a biotech company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. In this podcast episode, Dr. Randy Teel discusses the company's PROTAC protein degrader technology platform and its pipeline of clinical-stage assets, with a focus on vepdegestrant, the company's lead asset that is being co-developed together with partner Pfizer, for the treatment of women with early and locally advanced or metastatic ER+/HER2- breast cancer.

HLTH brings together all the ecosystem stakeholders each year to discuss the innovations that will help solve some of healthcare's biggest challenges. In this podcast episode, Noe Gutierrez, the Head of Commercial Operations at Genoplex, Inc., shares many of the key themes and insights from the biggest health tech conference of 2024.

Next Generation Gene Therapies is developing novel gene therapies for the treatment of many rare diseases. In this podcast episode, the company's Co-Founder and Chief Operating Officer, Guang Qu, discusses how the company's dual-functional vector tech platform is being used to target many diseases.

Immunotherapies continue to redefine treatment for many types of cancer and one of the first immunotherapies approved and used clinically as a therapeutic is Interleukin-2, or IL-2. Aulos Bioscience is an immuno-oncology company that has developed AU-007, a potential best-in-class IL-2, that improves on many of the other IL-2 products in development. In this episode, we discuss the promise of AU-007 with President and CEO, Aron Knickerbocker. Link to Interleukin-2 review article can be found here: https://www.nature.com/articles/s41587-022-01390-3

In this podcast episode, we discuss the importance of addressing health equity for the rare disease community with Tamar Thompson, Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease. Tamar discussed her efforts to champion health policy, advocacy, equity, and awareness for rare diseases.

In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma. Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.

In this podcast episode, Dr. James Zou, Associate Professor of Biomedical Data Science and Faculty DIrector of the AI for Health department at Stanford University, shares current use cases for AI in healthcare and oncology and discusses how we can overcome challenges with LLMs to unlock the full potential of AI.

In this episode, Genoplex Founder and CEO, Chris Leidli, and CTO, Shoukri Kattan, take a dive deep into their shared passion for health, wellness, and longevity, and explore how technology is revolutionizing patient access to advanced therapies. Chris and Shoukri discuss the groundbreaking work happening at Genoplex, including how the company's Advanced Therapy Connect digital platform is transforming the way patients connect with life-changing treatments.

Our guest for this podcast episode is Robb Richards, Corporate Director of Cell Therapy and Transplant at University of Pennsylvania, Penn Medicine. In this episode, we discuss how Penn Medicine is working to improve patient access to cellular therapies and how technology has evolved to streamline operational and clinical workflows to enhance patient experience.

Our guest for this episode is Balaji Gopalan, CEO and Co-Founder of MedStack where we discuss how MedStack's tech stack is enabling digital health start-ups to be healthcare data compliant. MedStack streamlines compliance with out-of-the-box HIPAA controls and ready-to-use privacy policies, enabling the faster and more cost-effective development of digital health applications. With built-in security controls and third-party validation, MedStack is setting new standards in healthcare technology.

Our guest for this podcast episode is Mike Kelly, President & CEO of NervGen Pharma. NervGen is a clinical-stage biotech company at the forefront of developing treatments that empower the nervous system to repair itself following damage from injury or disease.

In this podcast episode, your host, Chris Leidli, MS, MBA, goes beyond the ASCO 2024 headlines and puts a spotlight on the new clinical data for advanced therapies you don't want to miss.

In this episode, we preview the top American Society of Gene and Cell Therapy (ASGCT) 2024 annual meeting abstracts with guests Dr. Emily Walsh Martin from Tremont Therapeutics Consulting and Lynnea Olivarez, Incoming Chair of the ASGCT Communications Committee.

Over the years, electronic health records (EHRs) have revolutionized medical practice, digitizing patient data and streamlining care. But the current systems are not well suited to support collection of real-world data or the tracking of longitudinal outcomes across patient populations. This is particularly true for hematopoietic stem cell transplant and cellular therapies. Our special guest, Dr. Wayne Liang is a leader in the stem cell transplant and cell therapy informatics field. Wayne is Director of Informatics Education and Outreach at Children's Healthcare of Atlanta, he is also a pediatric hematologist/oncologist at Aflac Cancer & Blood Disorders Center, and Assistant Professor of Pediatrics at Emory University.

Our guest for this podcast episode is Simon Arkell, CEO of Ryght. Ryght is developing the next generation of safe and secure generative AI to empower Life Science companies to ingest real-time data and make actionable knowledge directly available to discovery, clinical, and commercial teams.

Our guest for this podcast episode is Doron Behar, MD, PhD, co-founder and CEO of Igentify, a digital health, artificial intelligence and genetic counseling company. In this episode, Dr. Behar shares how his company has developed a medical-grade tech platform that optimizes genomic workflows and produces AI-generated personalized genetic counseling for patients.

This episode features a preview of the American Society of Gene and Cell Therapy Annual Meeting scientific symposium on the impact of Generative AI on cell and gene therapy (CGT); best practices and real-world applications for communicators. Dr. Rory Bricker-Anthony shares insight into what attendees can expect to learn from the May 2024 session, including current tools and applications for CGT communicators.

Our guest in this podcast episode is Chris Dokomajilar, Founder and CEO of DealForma. DealForma's comprehensive life science database includes meticulously researched licensing deal financial comps, up-to-date profiles, and historic company and pipeline data. In this special spotlight episode, we take a deeper dive into the investment landscape for advanced therapies and also AI investment and partnership activity in the biopharma space.

We often don't get the chance to hear from survivors and patient advocates whose lives have been impacted by advanced medicines; so that makes this podcast episode special as we talk to Chris White, a cancer survivor who faced the unimaginable when diagnosed with Mucosal Melanoma in 2018—a rare and aggressive cancer which makes Chris's journey even more exceptional. Today, Chris is not just a survivor; he's a beacon of inspiration. He has redirected his energy towards advocacy, prevention, and raising awareness of the complexities associated with Mucosal Melanoma. Tune in to listen to Chris's extraordinary odyssey, exploring the challenges he faced throughout his treatment journey and proving that with resilience, determination, and hope, anything is possible.

Our guest for this podcast episode is Mark Carbone, the CEO of PN Medical. PN Medical is a leader in respiratory care and research. The company created “The Breather”, the world's first combined respiratory muscle training device to strengthen respiratory muscles to optimize blood flow, lung function and strengthen the cardiopulmonary system.

In part 2 of this special round table podcast series, we discuss the future trends and advances in cell therapy manufacturing and the impact of AI on the evolving cell therapy analytics space.

In part 1 of this special round table podcast series, we discuss the current trends and advances in cell therapy manufacturing and the impact of evolving manufacturing processes on the analytics space.

Our guest for this podcast episode is Laura Hobbs, Director of Healthcare Policy at the American Action Forum. In this episode, we discuss the Inflation Reduction Act impact on Pharma and Patient Access, along with 340b drug pricing and new PBM utilization controls. Learn more about the American Action Forum, and subscribe to their weekly newsletter here: https://www.americanactionforum.org/

In this special episode, listen to Emily Walsh Martin, PhD, Principal at Tremont Therapeutics Consulting, as she shares some of the key highlights from the American Society of Gene and Cell Therapy's Policy Summit that was held in Washington, DC, on September 18th and 19th, 2023. Check out the full program and register to view the on-demand content online at asgct.org/advocacy/policy-summit/agenda

The Inflation Reduction Act was signed into law in August 2022. In this podcast episode, we look into what lies ahead as the policy implementation begins. Our guest in this episode is Dr. Robert Popovian, a clinical pharmacist and health economist with deep expertise in health policy, drug pricing and affordability, access, and patient advocacy.

Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD. Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.

Listen to Francesca Cook, VP of Market Access at Regenexbio, as she provides an overview of the program and what to expect at the American Society of Gene and Cell Therapy's upcoming Policy Summit being held in Washington, DC, on September 18th and 19th, 2023. Check out the full program and register online at https://asgct.org/advocacy/policy-summit/agenda

In this podcast episode, our guest is Mark McDonough, CEO of ChromaCode. ChromaCode is an innovator in genomics with a multiplexing platform that is driving integration from laboratories to physicians to patients, connecting them to the right treatment through its proven HDPCR™ multiplexing platform. This adaptable technology expands the accessibility of diagnostic applications to patient communities with a cost effective and scalable dPCR-based solution compatible with existing instrumentation and using standard workflows

In this podcast episode, our guest is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins leveraging their Superkine Platform to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers.

In this podcast episode, Tomasz George, Chief Scientific Officer at Virax Biolabs, shares how the company's ViraxImmune™ technology platform will empower patients to take control of their health and make informed decisions on how to respond to current and future viral threats. The company hopes their ViraxImmune™ platform will shift the way individuals are able to manage aspects of their immune health.

In this podcast episode, Dr. Michael Alonso, VP of Immunology and Pharmacology at Bolt Biotherapeutics, discusses how the company is developing cancer therapies that engage the innate immune system to generate robust anti-tumor responses.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs. In this podcast episode, we speak with Gregory Flesher, President and CEO of Reneo to learn more about mavodelpar, the company's lead asset, which is being developed in two rare diseases, primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).

In this podcast episode, Cyclacel CEO and President, Spiro Rombotis, shares how the company, is exploiting deeper understanding of molecular oncology to develop novel precision medicines based on cell cycle, transcriptional regulation, and mitosis biology.

Chris Leidli reviews scientific and clinical highlights from the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting with guest, Benjamin McLeod, MBIOT.

In this podcast episode, Dr. Philip Kantoff, the CEO, CMO, and Co-Founder of Convergent Therapeutics reviews the company's efforts to develop next-generation radiopharmaceuticals for the treatment of cancer.

FibroBiologics is the leading biotech company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. In this podcast episode, the Founder and CEO, Pete O'Heeron discusses the promise of fibroblast cell therapy to treat diseases such as multiple sclerosis, degenerative disk disease and more.

In this podcast episode, Dr. Erandi De Silva discusses the hybrid approach to gene therapy development at Forge Biologics, Inc., an emerging leader in the contract development and manufacturing (CDMO) market for advanced regenerative medicine products. Dr. De Silva also discusses the unique approach to building a culture and diverse talent pool within the Columbus, Ohio biotech ecosystem.

Forge Biologics is on a mission to enable access to life-changing gene therapies and help bring them from idea into reality. In this podcast episode, we learn about trends in the gene therapy landscape and contract manufacturing from Co-Founder and CEO, Timothy Miller, PhD.

This podcast episode previews the key precision medicine and cellular therapy data being showcased at this year's American Association of Cancer Research annual meeting.

Allen Davidoff, PhD is the Founder and CEO of XORTX Therapeutics, Inc., a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. This podcast episodes looks at novel therapies in development that may extend kidney health.

This podcast episode provides a short recap of the day long workshop hosted by the FDA's Office of Therapeutic Products (OTP) a new office within CBER. The goal of the workshop was to share knowledge and best practices from experts in the field of advanced manufacturing and analytical technologies (AMAT) for regenerative medicine therapies. Innovative manufacturing technologies and alternative testing methods were discussed along with, challenges and best practices critical for chemistry, manufacturing, and controls (CMC) of cellular and gene therapies and tissue engineered medical products.

As Life Science companies grow, they become less efficient. In this podcast episode, Dr. Donald Davis explains what scaling challenges are and what companies can do to become more efficient using the process improvement tools of lean six sigma.

Anyone who has experimented with ChatGPT can get a sense of the potential of generative AI. AI powers driverless cars, spots signs of disease on medical images, finds an answer when you ask Alexa a question, and lets you unlock your phone with your face to talk to friends on the iPhone. Those are just a few ways AI already touches our lives, but there are many ways AI is being utilized in the pharma industry. Applying AI to big data in pharma will reshape business models, streamline manufacturing, and enhance everything from early drug discovery and clinical trial data to supply chain applications and other market intelligence. It can also enable life sciences companies to be more personalized and authentic in how they engage with health care professionals, patients, and other stakeholders. In this podcast episode, we review the five main applications for AI in biotech, pharma and healthcare.

In this podcast episode, we recap highlights from JPM Healthcare conference with Chris Dokomajilar from DealForma, Inc., and review 2023 outlook for Biopharma Dealmaking, Financing, and Partnerships. To join live webinar on February 8th, 2023, use this link: https://us02web.zoom.us/j/6097872444

In this podcast episode, Chris provides a short preview of biotechnology and pharmaceutical companies to watch in 2023.